Alexis Ogdie1, Laura Coates2. 1. Division of Rheumatology, Departments of Medicine and Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, White Building Room 5023, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Alexis.ogdie@uphs.upenn.edu. 2. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK.
Abstract
PURPOSE OF THE REVIEW: We will address current treatment and unmet needs in psoriatic arthritis (PsA), examine existing randomized controlled trials (RCTs), and consider options for new trial designs and challenges in their implementation. RECENT FINDINGS: While therapeutic options for PsA have rapidly increased, there continues to be a need for clinical trials to test new therapies and establish optimal treatment strategies in order to improve the care for patients with PsA. In addition, more data is needed on how to select the best therapy for a given patient in clinical practice. Consideration of alternative outcome measures is also needed. Despite the rapid expansion in the number of therapy options available, there is still much to be learned about how to treat the individual patient with PsA.
PURPOSE OF THE REVIEW: We will address current treatment and unmet needs in psoriatic arthritis (PsA), examine existing randomized controlled trials (RCTs), and consider options for new trial designs and challenges in their implementation. RECENT FINDINGS: While therapeutic options for PsA have rapidly increased, there continues to be a need for clinical trials to test new therapies and establish optimal treatment strategies in order to improve the care for patients with PsA. In addition, more data is needed on how to select the best therapy for a given patient in clinical practice. Consideration of alternative outcome measures is also needed. Despite the rapid expansion in the number of therapy options available, there is still much to be learned about how to treat the individual patient with PsA.
Authors: A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale Journal: Ann Rheum Dis Date: 2004-11-04 Impact factor: 19.103
Authors: Wolfram Sterry; Jean-Paul Ortonne; Bruce Kirkham; Olivier Brocq; Deborah Robertson; Ronald D Pedersen; Joanne Estojak; Charles T Molta; Bruce Freundlich Journal: BMJ Date: 2010-02-02
Authors: Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler Journal: Arthritis Rheum Date: 2009-04
Authors: Asta Baranauskaite; Helena Raffayová; N V Kungurov; Anna Kubanova; Algirdas Venalis; Laszlo Helmle; Shankar Srinivasan; Evgeny Nasonov; Nathan Vastesaeger Journal: Ann Rheum Dis Date: 2011-10-12 Impact factor: 19.103
Authors: Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett Journal: Ann Rheum Dis Date: 2014-03-04 Impact factor: 19.103
Authors: Nicola Luigi Bragazzi; Charlie Bridgewood; Abdulla Watad; Giovanni Damiani; Jude Dzevela Kong; Dennis McGonagle Journal: Front Immunol Date: 2022-03-10 Impact factor: 7.561
Authors: Alexis Ogdie; Kelley Myers; Carol Mansfield; William Tillett; Peter Nash; Colton Leach; W Benjamin Nowell; Kelly Gavigan; Patrick Zueger; Erin McDearmon-Blondell; Jessica Walsh Journal: Rheumatol Ther Date: 2022-03-13